The deal aims to strengthen pharmaceutical partnerships and ensure equitable pricing policies.
AstraZeneca’s Chief Executive Officer met with former President
Donald Trump at the White House to finalize a Most Favored Nation agreement designed to promote fair drug pricing and expanded pharmaceutical cooperation.
The accord is expected to improve market transparency and align U.S. healthcare procurement practices with global standards.
Industry analysts say the move could set a precedent for future government negotiations with major drug manufacturers.